These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22115872)

  • 1. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
    Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
    J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
    Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Evaluation of INNO-LiPA HPV Genotyping
    Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus.
    Hwang Y; Lee M
    Ann Lab Med; 2012 May; 32(3):201-5. PubMed ID: 22563555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population.
    Jentschke M; Soergel P; Lange V; Kocjan B; Doerk T; Luyten A; Petry KU; Poljak M; Hillemanns P
    Int J Gynecol Cancer; 2012 Jul; 22(6):1050-6. PubMed ID: 22740006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test.
    Tang N; Huang S; Erickson B; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S25-8. PubMed ID: 19651365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection.
    Ko K; Kwon MJ; Lee EH; Woo HY; Park H
    J Clin Lab Anal; 2017 Mar; 31(2):. PubMed ID: 27387091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
    Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
    J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes.
    Barzon L; Militello V; Pagni S; Palù G
    J Clin Virol; 2012 Nov; 55(3):256-61. PubMed ID: 22877561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.
    Kaliterna V; Židovec Lepej S; Vince A
    J Med Microbiol; 2009 Dec; 58(Pt 12):1662-1663. PubMed ID: 19661205
    [No Abstract]   [Full Text] [Related]  

  • 15. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
    Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
    J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
    Huang S; Erickson B; Tang N; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S19-23. PubMed ID: 19651364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.
    Safaeian M; Herrero R; Hildesheim A; Quint W; Freer E; Van Doorn LJ; Porras C; Silva S; González P; Bratti MC; Rodriguez AC; Castle P;
    J Clin Microbiol; 2007 May; 45(5):1447-54. PubMed ID: 17344361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
    Yu S; Kwon MJ; Lee EH; Park H; Woo HY
    J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.